Deutsch English Français

Contact

EP1254374

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP1254374

EP1254374 - METHOD FOR DIAGNOSING EFFICACY OF XENOTYPIC ANTIBODY THERAPY [Right-click to bookmark this link]
Status	No opposition filed within time limit Status updated on 22.02.2008 Database last updated on 03.10.2024
Most recent event Tooltip	24.10.2008	Lapse of the patent in a contracting state	published on 26.11.2008 [2008/48]
Applicant(s)	For all designated states AltaRex Medical Corporation 8223 Roper Road NW Edmonton Alberta T6E 6S4 / CA
	[2006/12]
Former [2004/22]	For all designated states AltaRex Medical Corp. 1123 Dentistry/Pharmacy Building, University of Alberta Edmonton, Alberta T6G 2N8 / CA
Former [2002/45]	For all designated states Altarex Corp. 1123 Dentistry Pharmacy Building, University of Alberta Edmonton, Alberta T6G 2N8 / CA
Inventor(s)	01 / NOUJAIM, Antoine 58 Wilkin Road Edmonton, Alberta T6M 2K4 / CA
	[2002/45]
Representative(s)	Chapman, Paul Gilmour, et al Marks & Clerk LLP The Beacon 176 St Vincent Street Glasgow G2 5SG / GB
	[N/P]
Former [2003/32]	Chapman, Paul Gilmour, et al Cruikshank & Fairweather, 19 Royal Exchange Square Glasgow G1 3AE / GB
Former [2002/45]	Hinterberg, Katherine, et al Cabinet Germain et Maureau, BP 6153 69466 Lyon Cedex 06 / FR
Application number, filing date	01912066.6	08.02.2001
	[2002/45]
	WO2001IB00423
Priority number, date	US20000181008P	08.02.2000 Original published format: US 181008 P
	US20000201868P	04.05.2000 Original published format: US 201868 P
	[2002/45]
Filing language	EN
Procedural language	EN
Publication	Type:	A2 Application without search report
	No.:	WO0159452
	Date:	16.08.2001
	Language:	EN
	[2001/33]
	Type:	A2 Application without search report
	No.:	EP1254374
	Date:	06.11.2002
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 16.08.2001 takes the place of the publication of the European patent application.
	[2002/45]
	Type:	B1 Patent specification
	No.:	EP1254374
	Date:	18.04.2007
	Language:	EN
	[2007/16]
Search report(s)	International search report - published on:	EP	18.07.2002
Classification	IPC:	G01N33/68	[2002/45]
	CPC:	G01N33/6854 (EP,US); G01N33/569 (EP,US); G01N33/574 (EP,US); G01N2333/96455 (EP,US)
Designated contracting states	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR [2002/45]
Extension states	AL	Not yet paid
	LT	Not yet paid
	LV	Not yet paid
	MK	Not yet paid
	RO	Not yet paid
	SI	Not yet paid
Title	German:	VERFAHREN ZUR DIAGNOSE DER EFFEKTIVITÄT DER XENOTYPISCHEN ANTIKÖRPERTHERAPIE	[2002/45]
	English:	METHOD FOR DIAGNOSING EFFICACY OF XENOTYPIC ANTIBODY THERAPY	[2002/45]
	French:	DETERMINATION DE L'EFFICACITE D'UNE THERAPIE PAR ANTICORPS XENOTYPIQUES	[2002/45]
Entry into regional phase	08.08.2002	National basic fee paid
	08.08.2002	Designation fee(s) paid
	08.09.2002	Examination fee paid
Examination procedure	28.08.2001	Request for preliminary examination filed International Preliminary Examining Authority: EP
	08.09.2002	Examination requested [2002/50]
	30.04.2004	Despatch of a communication from the examining division (Time limit: M06)
	08.11.2004	Reply to a communication from the examining division
	03.03.2005	Despatch of a communication from the examining division (Time limit: M06)
	13.09.2005	Reply to a communication from the examining division
	06.10.2006	Cancellation of oral proceeding that was planned for 10.10.2006
	06.10.2006	Minutes of oral proceedings despatched
	10.10.2006	Date of oral proceedings (cancelled)
	10.11.2006	Communication of intention to grant the patent
	03.03.2007	Fee for grant paid
	03.03.2007	Fee for publishing/printing paid
Divisional application(s)	EP07007737.5 / EP1821104
Opposition(s)	21.01.2008	No opposition filed within time limit [2008/13]
Fees paid	Renewal fee
	17.02.2003	Renewal fee patent year 03
	23.02.2004	Renewal fee patent year 04
	22.02.2005	Renewal fee patent year 05
	27.02.2006	Renewal fee patent year 06
	27.02.2007	Renewal fee patent year 07
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition Tooltip	GR	19.07.2007
	[2008/48]
Cited in	International search	[X] - SCHULTES BIRGIT C ET AL, "Anti-idiotype induction therapy: Anti-CA125 antibodies (AB3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1).", CANCER IMMUNOLOGY IMMUNOTHERAPY, (199806), vol. 46, no. 4, ISSN 0340-7004, pages 201 - 212, XP002194278 [X] 1-25 * the whole document * DOI: http://dx.doi.org/10.1007/s002620050479
		[X] - MADIYALAKAN R ET AL, "Antiidiotype Induction Therapy: Evidence for the Induction of Immune Response through the Idiotype Network in Patients with Ovarian Cancer after Administration of Anti-CA125 Murine Monoclonal Antibody B43.13.", HYBRIDOMA, (1995), vol. 14, no. 2, ISSN 0272-457X, pages 199 - 203, XP001064580 [X] 1-25 * the whole document *
		[X] - QI W ET AL, "Induction of idiotype network to anti-MUC-1 antibody in breast cancer.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, 89th Annual Meeting of the American Association for Cancer Research;New Orleans, Louisiana, USA; March 28-April 1, 1998, March, 1998, (199803), vol. 39, ISSN 0197-016X, page 367, XP002194279 [X] 1-25 * abstract *
		[X] - REINARTZ S ET AL, "Evaluation of immunological responses in patients with ovarian cancer treated with the anti-idiotype vaccine ACA125 by determination of intracellular cytokines-A preliminary report.", HYBRIDOMA, (199902), vol. 18, no. 1, ISSN 0272-457X, pages 41 - 45, XP001064593 [X] 1-25 * the whole document *
		[X] - SCHLEBUSCH HARALD ET AL, "A Monoclonal Antiidiotypic Antibody ACA 125 Mimicking the Tumor-Associated Antigen CA 125 for Immunotherapy of Ovarian Cancer.", HYBRIDOMA, (1995), vol. 14, no. 2, ISSN 0272-457X, pages 167 - 174, XP001064579 [X] 1-25 * the whole document *
		[X] - KOEHLER S ET AL, "Immunotherapy of ovarian carcinoma with the monoclonal anti-idiotype antibody ACA125: Results of the phase Ib study.", GEBURTSHILFE UND FRAUENHEILKUNDE, (199804), vol. 58, no. 4, ISSN 0016-5751, pages 180 - 186, XP001064559 [X] 1-25 * the whole document *
		[A] - LEVEUGLE B ET AL, "PSA-directed immunotherapy of prostate cancer.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, 89th Annual Meeting of the American Association for Cancer Research;New Orleans, Louisiana, USA; March 28-April 1, 1998, March, 1998, (199803), vol. 39, ISSN 0197-016X, page 355, XP002194280 [A] 1-25 * abstract *
		[A] - WAGNER U A ET AL, "IMMUNOTHERAPY OF ADVANCED OVARIAN CARCINOMAS BY ACTIVATION OF THE IDIOTYPIC NETWORK", BIOTECHNOLOGY THERAPEUTICS, (1992), vol. 3, no. 1-2, ISSN 0898-2848, pages 81 - 89, XP001053690 [A] 1-25 * the whole document *

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 35p